Overview

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Treatments:
Thyrotropin-Releasing Hormone
Criteria
Inclusion Criteria:

- SCD with mild to moderate ataxia

Exclusion Criteria:

- Patients with secondary ataxia

- Patients with clinically significant hepatic, renal, or cardiovascular dysfunction